|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Cancer Institute: Information
Technology Division, . http://www.nci.go.th/th/cancer_record/cancer_rec1.htmlAccessed.
November 1–2014
|
|
3
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burstein HJ, Chen YH, Parker LM, et al:
VEGF as a marker for outcome among advanced breast cancer patients
receiving anti-VEGF therapy with bevacizumab and vinorelbine
chemotherapy. Clin Cancer Res. 14:7871–7877. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miles DW, de Haas SL, Dirix LY, et al:
Biomarker results from the AVADO phase 3 trial of first-line
bevacizumab plus docetaxel for HER2-negative metastatic breast
cancer. Br J Cancer. 108:1052–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schneider BP, Wang M, Radovich M, et al:
ECOG 2100: Association of vascular endothelial growth factor and
vascular endothelial growth factor receptor-2 genetic polymorphisms
with outcome in a trial of paclitaxel compared with paclitaxel plus
bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol.
26:4672–4678. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O-Charoenrat P, Rhys-Evans P, Modjtahedi H
and Eccles SA: Vascular endothelial growth factor family members
are differentially regulated by c-erbB signaling in head and neck
squamous carcinoma cells. Clin Exp Metastasis. 18:155–161. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sa-Nguanraksa D and O-Charoenrat P: The
role of vascular endothelial growth factor a polymorphisms in
breast cancer. Int J Mol Sci. 13:14845–14864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng S, Song QK, Ren Y, et al: The
characteristics of breast cancer subtypes: Implications for
treatment guidelines and individualized treatment strategies in
China. Appl Immunohistochem Mol Morphol. 22:383–389. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dawood S, Hu R, Homes MD, Collins LC,
Schnitt SJ, Connolly J, Colditz GA and Tamimi RM: Defining breast
cancer prognosis based on molecular phenotypes: Results from a
large cohort study. Breast Cancer Res Treat. 126:185–192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Linderholm B, Bergqvist J, Hellborg H,
Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L and
Bergh J: Shorter survival-times following adjuvant endocrine
therapy in oestrogen- and progesterone-receptor positive breast
cancer overexpressing HER2 and/or with an increased expression of
vascular endothelial growth factor. Med Oncol. 26:480–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berns EM, Klijn JG, Look MP, et al:
Combined vascular endothelial growth factor and TP53 status
predicts poor response to tamoxifen therapy in estrogen
receptor-positive advanced breast cancer. Clin Cancer Res.
9:1253–1258. 2003.PubMed/NCBI
|
|
14
|
Rydén L, Stendahl M, Jonsson H, Emdin S,
Bengtsson NO and Landberg G: Tumor-specific VEGF-A and VEGFR2 in
postmenopausal breast cancer patients with long-term follow-up.
Implication of a link between VEGF pathway and tamoxifen response.
Breast Cancer Res Treat. 89:135–143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Tamimi RM, Collins LC, Schnitt SJ,
Gilmore HL, Connolly JL and Colditz GA: The association between
vascular endothelial growth factor expression in invasive breast
cancer and survival varies with intrinsic subtypes and use of
adjuvant systemic therapy: Results from the Nurses' Health Study.
Breast Cancer Res Treat. 129:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
